Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2019-08-08 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
2019年上半年募集资金存放和实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company through its initial public offering (IPO). It includes specifics about the amount raised, the investment projects funded, the use of idle funds, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the management of raised funds. It also includes audited figures and a detailed table of fund usage. The document length is 8231 characters, which is substantial and contains actual financial data and analysis related to the use of raised capital. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and the use of capital. It is not an announcement of a report publication, nor a general regulatory filing, nor a full annual or interim report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-08-08 Chinese
招商证券股份有限公司关于郑州安图生物工程股份有限公司新增募集资金投资项目实施地点的核查意见
Capital/Financing Update Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the addition of an investment project implementation location for a company's newly raised funds. It discusses the use of proceeds from a convertible bond issuance, compliance with regulatory requirements, and internal approvals. The content focuses on the management and use of raised funds, specifically an update on the investment project location, rather than the issuance of a new report or financial results. The document is relatively short (2276 characters) and is a formal opinion or verification related to capital raising activities. This fits best under the category of Capital/Financing Update (CAP), as it relates to updates on the use and management of raised capital funds and project implementation details. It is not an announcement of a report publication, nor a full financial report, nor a regulatory filing of a different nature. Therefore, the classification is CAP with high confidence.
2019-08-08 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding a change in accounting policies. It details the nature of the accounting policy changes, references specific accounting standards issued by the Ministry of Finance, and explains the impact on financial statements. The document includes the board of directors', independent directors', and supervisory board's opinions on the change. It does not contain actual financial statements or comprehensive financial data but rather explains the policy change and its implications. The document length is 3123 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting policy changes without substantive financial data or full financial reports.
2019-08-08 Chinese
独立董事关于公司第三届董事会第八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Zhengzhou Antu Bioengineering Co., Ltd. regarding resolutions passed at the company's third board of directors' eighth meeting. It discusses approval of cash management using idle funds, changes in fundraising project locations, and accounting policy changes. The document references compliance with regulatory guidelines and company articles but does not contain financial statements or detailed financial data. It is a governance-related document expressing independent directors' opinions on board matters rather than a full report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board meeting matters, not an AGM presentation or voting results announcement.
2019-08-08 Chinese
关于新增募集资金投资项目实施地点的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the addition of an implementation location for a fundraising investment project. It details the background of the fundraising, the use of funds, and approvals from the board, independent directors, supervisors, and the sponsoring institution. The document does not contain financial statements or detailed financial data but focuses on the update about the use of raised capital and project implementation location. It is not a full financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it provides an update on the use of raised funds and investment project details.
2019-08-08 Chinese
第三届董事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's third board of directors' eighth meeting. It details the meeting's convening, attendance, and voting results on various agenda items, including approval of the 2019 semi-annual report and other financial and operational matters. The document does not contain the actual semi-annual report or detailed financial data but refers to the report being disclosed on the stock exchange website. The document is short (1340 characters) and serves as a meeting resolution announcement rather than a full financial report. This fits the category of Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2019-08-08 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.